CVE:VPT

VentriPoint Diagnostics Competitors

C$0.52
-0.03 (-5.45 %)
(As of 04/22/2021 03:59 PM ET)
Add
Compare
Today's Range
C$0.51
Now: C$0.52
C$0.56
50-Day Range
C$0.38
MA: C$0.49
C$0.61
52-Week Range
C$0.07
Now: C$0.52
C$0.67
Volume860,364 shs
Average Volume3.61 million shs
Market CapitalizationC$65.05 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

VentriPoint Diagnostics (CVE:VPT) Vs. AKU, LXG, SQD, SVA, GEN, and LMD

Should you be buying VPT stock or one of its competitors? Companies in the industry of "diagnostics & research" are considered alternatives and competitors to VentriPoint Diagnostics, including Akumin (AKU), LexaGene (LXG), SQI Diagnostics (SQD), Sernova (SVA), GeneNews (GEN), and LED Medical Diagnostics (LMD).

Akumin (TSE:AKU) and VentriPoint Diagnostics (CVE:VPT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk and valuation.

Valuation & Earnings

This table compares Akumin and VentriPoint Diagnostics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AkuminC$246.08 million1.08C$-25,194,260.00C($0.36)-10.58
VentriPoint DiagnosticsC$37,517.001,733.89C$-4,128,201.00C($0.03)-15.76

VentriPoint Diagnostics has lower revenue, but higher earnings than Akumin. VentriPoint Diagnostics is trading at a lower price-to-earnings ratio than Akumin, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Akumin and VentriPoint Diagnostics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AkuminN/AN/AN/A
VentriPoint DiagnosticsN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Akumin and VentriPoint Diagnostics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Akumin01102.50
VentriPoint Diagnostics0000N/A

Akumin currently has a consensus target price of C$4.25, suggesting a potential upside of 10.39%. Given Akumin's higher possible upside, analysts clearly believe Akumin is more favorable than VentriPoint Diagnostics.

Summary

Akumin beats VentriPoint Diagnostics on 4 of the 7 factors compared between the two stocks.

VentriPoint Diagnostics (CVE:VPT) and LexaGene (CVE:LXG) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership and analyst recommendations.

Profitability

This table compares VentriPoint Diagnostics and LexaGene's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VentriPoint DiagnosticsN/AN/AN/A
LexaGeneN/AN/AN/A

Valuation and Earnings

This table compares VentriPoint Diagnostics and LexaGene's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VentriPoint DiagnosticsC$37,517.001,733.89C$-4,128,201.00C($0.03)-15.76
LexaGeneN/AN/AN/AC($0.12)-5.88

LexaGene has lower revenue, but higher earnings than VentriPoint Diagnostics. VentriPoint Diagnostics is trading at a lower price-to-earnings ratio than LexaGene, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for VentriPoint Diagnostics and LexaGene, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
VentriPoint Diagnostics0000N/A
LexaGene0000N/A

Summary

VentriPoint Diagnostics beats LexaGene on 2 of the 3 factors compared between the two stocks.

SQI Diagnostics (CVE:SQD) and VentriPoint Diagnostics (CVE:VPT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for SQI Diagnostics and VentriPoint Diagnostics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SQI Diagnostics0000N/A
VentriPoint Diagnostics0000N/A

Profitability

This table compares SQI Diagnostics and VentriPoint Diagnostics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SQI DiagnosticsN/AN/AN/A
VentriPoint DiagnosticsN/AN/AN/A

Earnings and Valuation

This table compares SQI Diagnostics and VentriPoint Diagnostics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SQI DiagnosticsC$977,000.0099.38C$-12,264,984.00C($0.04)-7.92
VentriPoint DiagnosticsC$37,517.001,733.89C$-4,128,201.00C($0.03)-15.76

VentriPoint Diagnostics has lower revenue, but higher earnings than SQI Diagnostics. VentriPoint Diagnostics is trading at a lower price-to-earnings ratio than SQI Diagnostics, indicating that it is currently the more affordable of the two stocks.

Summary

VentriPoint Diagnostics beats SQI Diagnostics on 3 of the 5 factors compared between the two stocks.

VentriPoint Diagnostics (CVE:VPT) and Sernova (CVE:SVA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, dividends, earnings and risk.

Earnings and Valuation

This table compares VentriPoint Diagnostics and Sernova's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VentriPoint DiagnosticsC$37,517.001,733.89C$-4,128,201.00C($0.03)-15.76
SernovaN/AN/AN/AC($0.03)-54.44

Sernova has lower revenue, but higher earnings than VentriPoint Diagnostics. Sernova is trading at a lower price-to-earnings ratio than VentriPoint Diagnostics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and target prices for VentriPoint Diagnostics and Sernova, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
VentriPoint Diagnostics0000N/A
Sernova0000N/A

Profitability

This table compares VentriPoint Diagnostics and Sernova's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VentriPoint DiagnosticsN/AN/AN/A
SernovaN/AN/AN/A

Summary

VentriPoint Diagnostics beats Sernova on 2 of the 3 factors compared between the two stocks.

GeneNews (TSE:GEN) and VentriPoint Diagnostics (CVE:VPT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, risk, profitability and valuation.

Analyst Ratings

This is a breakdown of current recommendations and price targets for GeneNews and VentriPoint Diagnostics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
GeneNews0000N/A
VentriPoint Diagnostics0000N/A

Profitability

This table compares GeneNews and VentriPoint Diagnostics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GeneNewsN/AN/AN/A
VentriPoint DiagnosticsN/AN/AN/A

Valuation & Earnings

This table compares GeneNews and VentriPoint Diagnostics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GeneNewsC$234,592.000.00C$-11,557,484.00C($0.07)N/A
VentriPoint DiagnosticsC$37,517.001,733.89C$-4,128,201.00C($0.03)-15.76

VentriPoint Diagnostics has lower revenue, but higher earnings than GeneNews. VentriPoint Diagnostics is trading at a lower price-to-earnings ratio than GeneNews, indicating that it is currently the more affordable of the two stocks.

VentriPoint Diagnostics (CVE:VPT) and LED Medical Diagnostics (CVE:LMD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Valuation and Earnings

This table compares VentriPoint Diagnostics and LED Medical Diagnostics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VentriPoint DiagnosticsC$37,517.001,733.89C$-4,128,201.00C($0.03)-15.76
LED Medical DiagnosticsC$14.96 million1.04C$-1,512,615.00C($0.04)-10.26

LED Medical Diagnostics has higher revenue and earnings than VentriPoint Diagnostics. VentriPoint Diagnostics is trading at a lower price-to-earnings ratio than LED Medical Diagnostics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares VentriPoint Diagnostics and LED Medical Diagnostics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VentriPoint DiagnosticsN/AN/AN/A
LED Medical DiagnosticsN/AN/AN/A

Analyst Recommendations

This is a breakdown of current recommendations and price targets for VentriPoint Diagnostics and LED Medical Diagnostics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
VentriPoint Diagnostics0000N/A
LED Medical Diagnostics0000N/A

Summary

LED Medical Diagnostics beats VentriPoint Diagnostics on 3 of the 5 factors compared between the two stocks.


VentriPoint Diagnostics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
AKU
Akumin
0.9$3.85-1.8%C$266.48 millionC$246.08 million-10.58
LXG
LexaGene
0.5$0.70-1.4%C$83.27 millionN/A-5.88Gap Down
SQD
SQI Diagnostics
0.9$0.29-1.8%C$52.59 millionC$977,000.00-7.92
SVA
Sernova
0.5$1.47-0.0%C$31.35 millionN/A-54.44
GEN
GeneNews
0.5N/AN/AC$24.65 millionC$234,592.00-2.21
LMD
LED Medical Diagnostics
0.4$0.40-100.0%C$15.51 millionC$14.96 million-10.26Gap Down
IDL
Imaging Dynamics
0.4$0.08-13.3%C$4.13 millionC$378,253.00-3.95Gap Down
DXD
3D Signatures
0.5$0.04-100.0%C$2.66 millionN/A-0.91Gap Down
MBI
Med Biogene
0.5$0.05-22.2%C$795,000.00N/A-7.50Gap Up
BUX
(BUX)
0.5N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
Gap Up
IME
12144
0.5N/AN/AC$0.00N/A0.00High Trading Volume
Gap Down
CRL
Charles River Laboratories International
0.5N/AN/A$0.00N/A0.00Gap Up
SENS
Senseonics
0.0N/AN/A$0.00$4.95 million0.00High Trading Volume
This page was last updated on 4/22/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.